药品详细
Bevantolol(贝凡洛尔)
化学结构式图
中文名
贝凡洛尔
英文名
Bevantolol
分子式
C20H27NO4
化学名
[2-(3,4-dimethoxyphenyl)ethyl][2-hydroxy-3-(3-methylphenoxy)propyl]amine
分子量
Average: 345.4327
Monoisotopic: 345.194008357
Monoisotopic: 345.194008357
CAS号
59170-23-9
ATC分类
C07A 未知
药物类型
small molecule
阶段
approved
商品名
同义名
基本介绍
Bevantolol is a beta-1 adrenoceptor antagonist that has been shown to be as effective as other beta blockers for the treatment of angina pectoris and hypertension. Mechanism of Action Animal experiments confirm both agonist and antagonist effects on alpha-receptors, in addition to antagonist activity at beta-1 receptors.
生产厂家
封装厂家
参考
Synthesis Reference | Not Available |
General Reference |
|
剂型
规格
化合物类型
Type | small molecule |
Classes |
|
Substructures |
|
适应症
药理
Indication | For the treatment of angina pectoris and hypertension. |
Pharmacodynamics | Bevantolol is a beta-1 adrenoceptor antagonist that has been shown to be as effective as other beta blockers for the treatment of angina pectoris and hypertension. |
Mechanism of action | Animal experiments confirm both agonist and antagonist effects on alpha-receptors, in addition to antagonist activity at beta-1 receptors. By binding and antagonizing beta-1 receptors Bevantolol inhibits the normal normal epinephrine-mediated sympathetic actions such as increased heart rate. This has the effect of decreasing preload and blood pressure. |
Absorption | Not Available |
Volume of distribution | Not Available |
Protein binding | Not Available |
Metabolism |
Not Available
|
Route of elimination | Not Available |
Half life | Not Available |
Clearance | Not Available |
Toxicity | Not Available |
Affected organisms |
|
Pathways | Not Available |
理化性质
Properties | |||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
State | solid | ||||||||||||||||||||||||||||||||||||||||||
Experimental Properties |
|
||||||||||||||||||||||||||||||||||||||||||
Predicted Properties |
|
药物相互作用
Drug | Interaction |
---|---|
Chlorpropamide | The beta-blocker, bevantolol, may decrease symptoms of hypoglycemia. |
Clonidine | Increased hypertension when clonidine stopped |
Dihydroergotamine | Ischemia with risk of gangrene |
Disopyramide | The beta-blocker, bevantolol, may increase the toxicity of disopyramide. |
Epinephrine | Hypertension, then bradycardia |
Ergotamine | Ischemia with risk of gangrene |
Fenoterol | Antagonism |
Formoterol | Antagonism |
Gliclazide | The beta-blocker, bevantolol, may decrease symptoms of hypoglycemia. |
Glyburide | The beta-blocker, bevantolol, may decrease symptoms of hypoglycemia. |
Ibuprofen | Risk of inhibition of renal prostaglandins |
Indomethacin | Risk of inhibition of renal prostaglandins |
Insulin Glargine | The beta-blocker, bevantolol, may decrease symptoms of hypoglycemia. |
Methysergide | Ischemia with risk of gangrene |
Orciprenaline | Antagonism |
Pipobroman | Antagonism |
Piroxicam | Risk of inhibition of renal prostaglandins |
Prazosin | Risk of hypotension at the beginning of therapy |
Repaglinide | The beta-blocker, bevantolol, may decrease symptoms of hypoglycemia. |
Terbutaline | Antagonism |
食物相互作用
Not Available